Replies to post #488832 on NorthWest Biotherapeutics Inc (NWBO)

[FeMike]

I don't believe that the company would seriously dilute at todays prices. Once the trial is fully documented by the Journal and the company has ended the quiet period and brought the status of their activities over nearly the last two years up to date I believe our share price will be substantially higher.

While I believe that you believe what you say, the sad truth in dev stage bio techs is that the phrase “I don’t believe the company would seriously dilute at these prices” is often very famous last words.

The reality is that the company would absolutely dilute at these prices, and they have no real reason not to. Investors think they have some best interest in mind, but they don’t. Executing an RS and offering with serious dilution impacts the potential of the company none. It impacts the investors heavily. But I cannot stress this enough. They don’t care about retail investors. They care about institutional investors and that’s what they’re going to attract after the RS. And that’s why there aren’t any institutions invested now.

The quicker you accept this the quicker you will get better returns in bio tech. It’s not fud, it’s not criticism, it’s reality. If you think the execs of this or any company have your best interests in mind you are sadly mistaken. It’s a dog eat dog world.

And Dave, Les, I know you both read my posts. If you disagree I’ll fly to meet you at my own expense and let you explain to me why I’m wrong over a beer. I’ve been in this game too long. I am taking my original stance that you and the exec team are unethical.

As it stands, I’ve asked directly about the financial situation and have been dodged enough that I recognize investors are in for a rough Q3. Despite the fact that I think the company is going to boom in ‘23. The two are not mutually exclusive and it’s just poor ethics that gets us to this point.